Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | April 2013 |
| End Date: | December 2015 |
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line Treatment for Patients With Advanced Biliary Cancer
The primary purpose of this study is to determine the effectiveness of SPI-1620 in
combination with docetaxel in patients with advanced biliary cancer.
combination with docetaxel in patients with advanced biliary cancer.
Inclusion Criteria:
- Histologically confirmed biliary tract or gallbladder cancer that have relapsed or
are refractory after one prior gemcitabine-based chemotherapy regimen for advanced
biliary cancer
- Evaluable disease
- ECOG PS ≤ 2
- Adequate bone marrow, liver and renal function
Exclusion Criteria:
- Treatment with more than one prior chemotherapy regimen
- Known, uncontrolled CNS metastases
- Baseline peripheral neuropathy ≥ grade 2.
- Significant circulatory disorders in the past 6 months
- Concomitant use of phosphodiesterase inhibitors
We found this trial at
6
sites
The West Clinic, PC Hello and welcome to our office. Although it is our pleasure...
Click here to add this to my saved trials
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials